Generic Name and Formulations:
Brinzolamide 1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for AZOPT:
Open-angle glaucoma. Ocular hypertension.
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if serious systemic, ocular (eg, conjunctivitis, lid edema), or hypersensitivity reactions occur. Soft contact lenses (remove; may reinsert 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant oral carbonic anhydrase inhibitors: not recommended. Separate administration of other oph drugs by ≥10 minutes.
Carbonic anhydrase inhibitor (sulfonamide).
Blurred vision, bitter/sour taste, blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia; ocular discharge, discomfort, or itch; keratitis, rhinitis.
Susp—2.5mL, 5mL, 10mL, 15mL
- 10ml of 1% eye droppers (Qty:1)
- appx. price $264.00
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- Spiriva Respimat Gains Indication and New Dosage Strength
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC Guidelines on Preventing Sexual Transmission of Zika Virus Issued
- CDC Updates Interim Zika Virus Guidelines for Pregnant Women and Women of Reproductive Age
- Daklinza Use Expanded to Cover Treatment in More HCV Patients
- Researchers Call for an Alternative Tdap Immunization Strategy for Adolescents
- FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic